Dietary modification may be beneficial to patients with acromegaly, as nutrition may affect the hormones involved in disease pathophysiology. The driver of acromegaly has been well-characterized for ...

Acromegaly is a rare hormonal disorder in which the body produces excessive growth hormone (GH), leading to abnormal growth of certain body parts. It stems from a benign tumor that sits on the ...

An early postoperative adjusted IGF-1 of less than or equal to 1.32 ULN optimally predicted 3-month remission, yielding a sensitivity of 60%, specificity of 100%, positive predictive value of 100%, ...

The journal Pituitary has highlighted research led by Manel Puig, head of the Endocrine, Thyroid and Obesity Research Group at the Germans Trias i Pujol Research Institute (IGTP), which explores the ...

Palsonify is a medicine for certain people with acromegaly. Acromegaly is a rare disorder that happens when your body makes too much growth hormone (GH). This hormone is made and released in the ...

Crinetics Pharmaceuticals (NASDAQ:CRNX) has received approval for its lead asset, Palsonify (paltusotine), as a first-line treatment for adults with acromegaly, a rare condition characterized by ...

Credit: Crinetics. Palsonify is supplied as a 20mg and 30mg tablet. Palsonify is an oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist. The Food and Drug Administration (FDA) ...

What Is Palsonify, and Why Does It Matter? Palsonify (paltusotine) is a new once-daily oral medicine approved to treat adults with acromegaly who either didn’t get much help from surgery or cannot ...

After nearly two decades in the endocrine scene, Crinetics is making its commercial debut with the approval of a game-changing treatment for the rare growth disorder acromegaly. The FDA on Thursday ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Crinetics Pharmaceuticals won Food and Drug Administration approval on ...

Patients with acromegaly had significantly higher odds of developing leukemia/lymphoma or ovarian, breast, lung, or other cancers, many of which occurred at younger ages than typically seen in the ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, ...